Supporting information for: Selective inhibitors of human neuraminidase 1 (NEU1)

Tianlin Guo[‡], Rachel Héon-Roberts[†], Chunxia Zou[‡], Ruixiang Zheng[‡], Alexey V. Pshezhetsky[†], and Christopher W. Cairo[‡]*

†Division of Medical Genetics, Sainte-Justine University Hospital Research Center, University

of Montreal, Montréal, H3T 1C5, Canada

‡Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta,

T6G 2G2, Canada

*Correspondence: University of Alberta, Edmonton, Alberta, T6G 2G2. 780-492-0377 tel., 780-

492-8231 fax., ccairo@ualberta.ca

Table of Contents

Protein expression	
Table S1: HPLC Gradient elution used to check purity of inhibitors	S2
Table S2: Summary of HPLC and HRMS data for tested compounds	S3
Figure S1: Inhibition of human neuraminidase isoforms	S5
Table S3: K_i determinations using a noncompetitive inhibition model ^{<i>a</i>}	S51
Figure S2: Curves for <i>K</i> _i determinations using a competitive inhibition model and Li Burke plots.	ineweaver- S52
Figure S3: NMR (¹ H and ¹³ C) spectra	S57
Figure S4: HPLC traces	S103
References	S119

Protein expression

Optimized Neu3 and Neu4 genes were synthesized and subcloned into vector pMAL-c2x in DNA2.0. The plasmids of MBP-Neu3 and MBP-Neu4 were transformed into expression cells, *E. coli* TB1. Protein was isolated by culturing *E. coli* TB1 cells containing plasmid pMBP-*Neu3* or *Neu4* in LB medium containing 0.2% glucose and ampicillin (100 μ g/mL). The culture was grown at 30 °C with shaking until the OD₆₀₀ reached 0.3. The temperature was decreased to 20 °C, and fusion protein was induced by adding IPTG to a final concentration of 0.3 mM when OD₆₀₀ reached 0.5-0.6. Cells were harvested by centrifugation after 20 h of induction. The pellet was resuspended (50 mL per liter of medium) in resuspension buffer (20 mM MOPS, pH 7.2, 300 mM NaCl, 1mM EDTA, 10% glycerol and 0.05% triton X-100) and supplemented with a protease inhibitor tablet (Roche). The lysate was passed through a cell disruptor once at 20,000 psi and then immediately pelleted by centrifugation at 105,000 x g for 60 min at 4 °C. The supernatant was loaded onto an amylose column (New England Biolabs) equilibrated with 20 mM MOPS (10% glycerol and 300 mM NaCl, pH 7.2). MBP-fusion protein was eluted with running buffer containing 10% glycerol (v/v) and 10 mM maltose.

Table S1: HPLC Gradient elution used to check purity of inhibitors

Purity of compounds for enzymatic assay was tested by HPLC using a C18 reverse phase column (XTerra RP C18, analytical, particle size: 3.5 μ m, column dimensions: 4.8 \times 150 mm). The gradient elution program was summarized below where solvent A was 0.1% trifluoroacetic acid in milliQ water and solvent B was 0.1% trifluoroacetic acid in acetonitrile. See Figure S4 for HPLC traces.

Time	Flow rate (mL/min)	A%	B%
0	1	100	0
3	1	100	0
13	1	0	100
18	1	0	100

Compound	HPLC Trace		HRMS	
	Retention Time min	Area %	Calculated m/z	Found m/z
DANA (1)	1.657	98.70	290.0876	290.0879
Neu5AcN32en (6)	2.208	97.67	331.0890	331.0894
C9-BA-DANA (8)	1.864	99.97	373.1616	373.1614
11a	2.115	99.71	304.1032	304.1039
11b	3.562	96.09	318.1189	318.1196
11c	8.546	97.15	332.1345	332.1348
11d	9.866	98.07	346.1507	346.1506
11e	10.696	99.05	360.1664	360.1665
11f	3.586	99.13	318.1194	318.1193
11g	7.692	97.26	333.1351	333.1348
11h	9.950	97.93	346.1507	346.1496
11i	3.188	96.35	316.1032	316.1030
11j	4.858	95.21	330.1189	330.1195
11k	9.295	99.36	352.1038	352.1035
111	1.667	98.98	347.1460	347.1458
13a	8.342	96.24	448.1468	448.1481
13b	11.757	96.96	490.1574	490.1584
13c	5.140	99.78	448.1468	448.1481
13d	10.781	99.32	447.1516	447.1520
13e	13.667	97.20	463.1465	463.1471
13f	13.872	95.09	451.1265	451.1271
13g	13.403	95.96	501.1233	501.1243

 Table S2: Summary of HPLC and HRMS data for tested compounds

13h	12.199	97.12	477.1258	477.1268
13i	11.645	96.35	427.1834	427.1837
15a	8.088	97.62	359.1460	359.1453
15b	11.240	96.84	387.1773	387.1766
15c	12.120	96.14	401.1929	401.1931
15d	6.950	95.86	359.1460	359.1458
15e	10.131	95.32	373.1616	373.1617
15f	10.456	96.86	387.1773	387.1765
15g	10.141	97.23	393.1303	393.1302
15h	11.757	96.96	450.1518	450.1525
15i	4.455	99.32	408.1412	408.1415
15j	9.600	95.50	450.1518	450.1515
15k	5.202	97.68	408.1412	408.1411
151	9.447	96.58	549.2202	549.2207
15m	11.753	99.59	411.1885	411.1889
17a	12.937	98.19	443.2399	443.2396
17b	10.757	96.19	415.2086	415.2081
17c	11.769	99.89	387.1773	387.1770
17d	12.273	99.58	401.1929	401.1926
17e	11.351	98.88	373.1616	373.1615
17f	12.030	97.16	387.1773	387.1774
17g	12.084	96.27	401.1929	401.1929
17h	12.363	97.55	415.2086	415.2088
22	9.353	97.76	387.1885	387.1879

Figure S1: Inhibition of human neuraminidase isoforms

IC50 curves using 4MU-NANA as substrate

1(DANA)









11a













11g









11k





13a



















15a

15b





15c
































17e







17h



Compd.	NEU1		NEU2	
	α	$K_{i}[\mu M]$	α	$K_{\rm i}[\mu {\rm M}]$
DANA	4.4	17 ± 4	0.32	130 ± 99
8	1.2	1.6 ± 0.9	ND	
11c	infinite	0.24 ± 0.03	ND	
11d	4.7	0.25 ± 0.06	ND	
17f	7.2	0.066 ± 0.13	ND	
13c	ND		0.024	67 ± 476
13d	ND		0.69	11 ± 6
22	ND		12	1.7 ± 0.5

Table S3: *K*_i determinations using a noncompetitive inhibition model^{*a*}

^{*a*} Data were fit to a noncompetitive inhibition model, also called a mixed inhibition model, using the kinetic data shown in Fig S2 with the following equation¹:

$$\mathbf{V} = \frac{\mathbf{V}_{\max}[\mathbf{S}]}{[\mathbf{S}]\left(\mathbf{1} + \frac{[\mathbf{I}]}{\alpha K_i}\right) + K_m(\mathbf{1} + \frac{[\mathbf{I}]}{K_i})}$$

Figure S2: Curves for K_i determinations using a competitive inhibition model and Lineweaver-Burke plots.

DANA







Compound 11c with NEU1 Lineweaver-Burk plot of 11c with NEU1 $K_{\rm i}$ = 0.24 ± 0.03 µM Inhibitor/µM 60-Inhibitor/µM ● 0 0.6 **-** 0 0.041 -0.041152 40 0.12 0.4 0.123457 ۸ ₹ 0.37 Vmax -0.37037 v 1.11 • 0 1.111111 20 4 0.2 **-** 3.3 3.333333 0 + 10 10 0.0 -0.02 0.02 0.04 0.06 100 0.00 50 0 1/[S] Substrate/µM



17f

Compound 17f with NEU1







13d

Compound 13d with NEU2 Ki = 2.7 ± 0.6 μM Inhibitor/µM Lineweaver-Burk plot of 13d with NEU2 5-- 0 10-1 4 3 × 3-2-**∓** 10 ➡ 30 5 ₹ 2. **--** 90 00 6 0 -0.01 0.01 1/[S] 200 0.03 100 150 0.02 50 Substrate/µM

Inhibitor/µM

0 ٠

1

3

10 ▼

30 ٠ 0 100



Figure S3: NMR (¹H and ¹³C) spectra 1(DANA)

499.808 MHz H1 1D in CD₃OD



6(Neu5AcN32en)



8(C9-BA-DANA)

499.808 MHz H1 1D in CD₃OD



11a

499.808 MHz H1 1D in CD_3OD



499.808 MHz H1 1D in CD_3OD <5.89 5.89 0.95 0.95 но он н7 о-м он Т но он -соон 1.03 1.00 1.10 1.03 -06 2.23-2.94-.0 3.5 f1 (ppm) 1.0 6.5 6.0 5.5 5.0 4.5 4.0 3.0 2.5 2.0 1.5 0.5 125.691 MHz C13[H1] 1D in CD₃OD —20.31 —14.11 соон <u> Порин</u> 20 70 80 30 130 120 110 100 f1 (ppm) 210 200 190 180 170 160 150 140 90 60 50 40 20 10 (

11b

499.808 MHz H1 1D in CD_3OD <5.89 <5.88 но он н Д но он -соон 00 0.92 0.93 1.95-1.88-1.95-2.87-.0 4.5 1.5 6.5 6.0 5.5 5.0 4.0 3.5 f1 (ppm) 3.0 2.5 2.0 1.0 0.5 125.691 MHz C13[H1] 1D in CD₃OD -77.91 -71.30 -64.09 -64.09 -64.09 -64.09 -71.30 -64.09 -64.09 -64.09 -64.09 -64.07 -6 -соон 120 110 100 f1 (ppm) 20 210 200 190 180 170 160 150 140 130 90 80 70 60 50 40 30 20 10 Ċ 11d



11e



499.799 MHz H1 1D in CD₃OD $<_{5.93}^{5.94}$ 1.151.141.131.131.13но он н м м но он -соон -0-1.04<u>T</u> 1.01.1 1.10 1.04 J 1.00 1.03 1.12 5.88-.0 3.5 f1 (ppm) 6.5 6.0 5.5 5.0 4.5 4.0 3.0 2.5 2.0 1.5 1.0 0.5 0. 125.688 MHz C13[H1] DEPTq in CD₃OD 71.05 70.21 64.38 64.38 70.21 64.38 49.36 49.35 49.35 49.35 49.35 49.53 49.50 48.67 $<_{19.70}^{20.10}$ но он соон)0 190 180 170 160 150 140 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10 Ċ

499.808 MHz H1 1D in CD₃OD $<_{5.93}^{5.93}$ 0.97 0.97 0.95 -соон <u> прон</u> 1.00 Å 1.01 F 00.0 1.00-1 1.03-2.95-5.73 .0 3.5 f1 (ppm) 1.0 0. 6.5 6.0 5.5 5.0 4.5 4.0 3.0 2.5 2.0 1.5 0.5 125.688 MHz C13[H1] DEPTq in CD₃OD -78.18 -70.34 -70.34 -65.04 -65.04 -65.04 -65.04 -69.18 -49.18 -49.18 -48.67 -46.33 -27.43 $\angle 22.89$ $\angle 22.83$ но он н До м но он -соон -0)0 190 180 170 160 150 140 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10 Ċ

11g

11h





499.808 MHz H1 1D in CD_3OD ^{8.27}
^{8.25} <5.89 5.88 4.484.46 соон нό о́н 2.04 0.48 1.00-1 1.02 56.0 586.0 598-0 599-1 0.97-0.96 .0 4.5 f1 (ppm) 0. 4.0 3.0 2.5 2.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 3.5 1.5 1.0 0.5 125.691 MHz C13[H1] 1D in CD₃OD -49.09 -48.92 -48.58 $-15.10 \\ < \frac{8.10}{7.75}$ но он соон но он 110 100 f1 (ppm) 20 210 200 180 170 160 150 140 130 120 80 70 60 50 40 . 30 20 10 190 90 C 499.808 MHz H1 1D in CD₃OD





11k



111



1**3**a


13b



13c



13d



13e



13f





S79







13i





499.808 MHz H1 1D in CD_3OD $<_{5.93}^{5.93}$ 1.64 1.63 1.61 1.60 0.94 нон соон асни но он Щ 1.02 1.05-J 1.05 2.03-2.13-1.00 1.09-2.87-2.90 3.5 f1 (ppm) 2.0 0 6.0 4.5 1.0 0.5 . 6.5 5.5 5.0 4.0 3.0 2.5 1.5 0. 125.691 MHz C13[H1] 1D in CD₃OD 51.97 49.59 49.25 49.25 49.25 49.08 49.08 48.74 48.74 48.74 48.57 -44.40 -36.87 -29.28 нон соон Асни Но он 100 f1 (ppm) . 30 190 180 170 160 150 140 130 120 110 90 . 80 60 50 40 30 20 10 70

499.808 MHz H1 1D in CD₃OD $<_{5.92}^{5.93}$ соон AcHN 🗸 но он 1.034 F-00.1 1.03 1.03 1.42 1.42 1.02 1.89-] 00 2.00-3.94-2.94 .0 3.5 f1 (ppm) 0. 6.0 2.5 1.5 6.5 5.5 5.0 4.5 4.0 3.0 2.0 1.0 0.5 125.691 MHz C13[H1] 1D in CD₃OD ~71.55 ~70.24 ~67.98 --51.97 --44.41 --37.09 --32.58 --26.81 --23.45 соон но он .)0 190 180 170 160 150 140 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10 Ċ 15c



699.765 MHz H1 1D in CD₃OD 2.51 2.49 2.47 2.47 2.47 $<_{5.74}^{5.74}$ соон AcHN но он 0.98 0.67 1.12-0.98 -86.0 0.98-1.04-1.00-2.71 5.71-.0 3.5 f1 (ppm) 2.0 2.5 1.5 6.5 6.0 5.5 5.0 4.5 4.0 3.0 1.0 0.5 175.975 MHz C13[H1] DEPTq in CD₃OD --------36.28 ИН ОН соон ACHN 🗸 но он 110 100 f1 (ppm))0 120 80 70 50 40 30 10 Ċ 190 180 170 160 150 140 130 90 60 20

15d

699.765 MHz H1 1D in CD₃OD $<_{5.74}^{5.74}$ 0.96 соон Асни Но он 1.02-1.08-1.00-1.03-11.08-5.69-5.25 .0 1.0 3.5 f1 (ppm) 2.0 6.5 6.0 5.5 5.0 4.5 4.0 3.0 2.5 1.5 0.5 175.975 MHz C13[H1] DEPTq in CD₃OD -77.30 71.71 -70.26 27.42 22.77 22.75 22.74 чή ο Ηγ соон AcHNно он 0 190 180 170 160 150 140 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10 Ċ



499.799 MHz H1 1D in CD₃OD









15i



15j



15k



15m



17a



<5.75 <5.74 $\begin{array}{c} 1.00\\$ инон Н соон Т но он 1.04 1.02 0.88 1.07--00.1 1.07-11.03-1.89-2.02-3.91-5.87 .0 3.5 f1 (ppm) 0. 6.5 6.0 5.5 5.0 4.5 3.0 2.5 1.5 1.0 0.5 4.0 2.0 125.688 MHz C13[H1] 1D in CD₃OD /177.78 /176.97 71.51 68.40 68.40 68.40 68.40 49.23 49.23 44.27 36.89 36.89 36.89 23.45 23.45 NНОН Н -соон -0 К но он 100 f1 (ppm))0 80 50 190 180 170 160 150 140 130 120 110 90 70 60 40 30 20 10 Ċ

499.799 MHz H1 1D in CD₃OD

17b

17c



499.799 MHz H1 1D in CD₃OD ---5.89 ілнон НД -соон 1 но он 1.03-1.00 J 2.05--66.0 1.04-1.00 2.81-1.94-2.00-3.88 2.81 .0 3.5 f1 (ppm) 6.0 0. 6.5 5.5 5.0 4.5 4.0 3.0 2.5 2.0 1.5 1.0 0.5 125.688 MHz C13[H1] DEPTq in CD₃OD ~178.60 ~70.25 ~68.10 51.87 49.51 49.51 49.17 49.00 48.83 48.66 48.49 48.49 44.40 37.07 37.07 37.07 37.07 26.77 23.44 —14.27 —10.37 -соон но он 100 f1 (ppm) .)0 190 180 170 160 150 140 130 120 110 90 80 70 60 50 40 30 20 10 Ċ

499.799 MHz H1 1D in CD₃OD 1.135 1.136 1.137 1.137 1.134 1.134 1.134 1.134 1.134 `NH ОН соон <u> Паран</u> 0.78 - TW 1.09 1.09 1.09 1.04 2.13 00.1 1.92 2.05 00 2.85-2.71 .0 4.0 3.5 f1 (ppm) 2.5 2.0 1.5 1.0 0.5 0. 6.5 6.0 5.5 5.0 4.5 3.0 125.688 MHz C13[H1] DEPTq in CD₃OD —177.96 —174.02 ~71.69 ~68.08 ~68.08 ~68.08 ~93.57 ~93.59 ~93.19 ~93.19 ~93.19 ~94.58 ~93.19 ~94.58 ~93.19 ~94.58 ~95.00 ~144.58 ~36.90 NH ОН соон но он .)0 190 180 170 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10 Ċ 160 150 140

17e







17g



17h



22

Figure S4: HPLC traces 1(DANA)



	Retention Time	Area	% Area
1	0.992	206327	2.49
2	1.657	8083296	97.51

6(Neu5AcN32en)



8(C9-BA-DANA)





	Retention Time	Area	% Area
1	2.115	21117740	99.71
2	3.592	60690	0.29

11b



2.157	257098	1.71
3.562	14450419	96.09
9.520	331511	2.20

2



	Minutes		
	Retention Time	Area	% Area
1	9.952	92676	0.95
2	10.696	9692986	99.05



11g

11f



_			
	Retention Time	Area	% Area
1	1.533	24281	0.17
2	3.398	155851	1.09
3	7.692	13864145	97.26
4	8.622	59974	0.42
5	9.410	32166	0.23
6	9.666	30659	0.22
7	10.111	47474	0.33
8	10.791	40680	0.29









11h


















13h



1154296

2.88



2

12.888





















15k

























	Retention Time	Area	% Area
1	11.601	135485	2.45
2	12.363	5398484	97.55



References

1. Kenakin, T. P. Chapter 6 - Enzymes as Drug Targets. In *Pharmacology in Drug Discovery*, Kenakin, T. P., Ed. Academic Press: Boston, 2012; pp 105-124.